<DOC>
	<DOCNO>NCT02522650</DOCNO>
	<brief_summary>This cross-over study design test hypothesis amiloride reduce urinary protein excretion protect kidney rapid progression proteinuric kidney disease .</brief_summary>
	<brief_title>A Crossover Pilot Study Effect Amiloride Proteinuria</brief_title>
	<detailed_description>Patients proteinuric kidney disease enrol receive either amiloride triamterene first , similar diuretic act epithelial sodium channel ( ENaC ) amiloride , inhibit urokinase plasminogen activator receptor ( uPAR ) , use control . Then patient cross receive another medication . We postulate amiloride could beneficial patient proteinuric kidney disease could use adjunct therapy reduce proteinuria delay renal disease progression patient population . Specific Aim 1 : To examine effect amiloride 24 hour urine protein excretion patient proteinuric kidney disease . Specific Aim 2 : To study effect amiloride proteinuria reduction mediate suppress soluble urokinase plasminogen activator receptor ( suPAR ) expression . Study Design : The study include 3 phase . 30 patient recruit study . All patient need angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB ) daily least two month prior study . Phase 1 : Patients randomize receive either amiloride 5mg twice daily triamterene 50mg twice daily 8 week . Serum potassium monitor one week one week start phase 1 . If serum potassium remain equal less 5.0mmol/L , amiloride triamterene continue dose end phase 1 . If serum potassium equal 5.5 mmol/L , patient exit study , adverse event report . If serum potassium 5.1-5.4 mmol/L , monitor one week . If serum potassium 5.5 mmol/L , patient exit study , adverse event report . If serum potassium remain range , patient continue amiloride triamterene dose complete phase 1 . Phase 2 : patient discontinue amiloride triamterene washout 4 week , continue ACE inhibitor ARB . Phase 3 : patient cross triamterene amiloride 8 week . Use protocol describe phase 1 .</detailed_description>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Triamterene</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<criteria>Patient type proteinuric kidney disease Aged 1875 Proteinuria ≥1g/day estimate glomerular filtration rate ( eGFR ) ≥ 30ml/min/1.73m2 Clinical evidence lupus nephritis , HIV associate nephropathy eGFR &lt; 30ml/min/1.73m2 Requirement treatment mineralocorticoid receptor antagonist ( spironolactone , eplerenone ) Status post kidney transplant Received glucocorticoid steroid within six month Serum K &gt; 4.8 mmol/L Total carbon dioxide &lt; 17 mmol/L Hemoglobin &lt; 10 g/dl Contraindicated allergic loop diuretic potassium spar diuretic Abnormal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>amiloride</keyword>
	<keyword>proteinuric kidney disease</keyword>
	<keyword>urokinase plasminogen activator receptor</keyword>
	<keyword>proteinuria</keyword>
</DOC>